#ESTRO consensus guidelines on #GTV delineation and dose-escalation in #rectalcancer, published in ctRO, Clinical and Translational Radiation Oncology.
👉 bit.ly/4cnC4me #openaccess
#radiotherapy #radiationoncology #guideline
ALK+ #lungcancer often means staying on a TKI for years. If radiotherapy is needed for brain metastases or a growing spot, the big question is whether to continue the drug.
New ESMO–ESTRO guidance says combining them can increase side effects. #LCSM
www.sciencedirect.com/science/arti...
NOTABLE ARTICLE, January 2026 #MedicalPhysics: A generalizable dose prediction model for automatic radiotherapy planning based on physics‐informed priors and large‐kernel convolutions
https://aapm.onlinelibrary.wiley.com/doi/10.1002/mp.70272
Please join us in congratulating Tianyu Xiong et al
At #BTOG26, consultants will host a Career Development Session for Trainees - An informal session for trainees of any grade interested in a career in thoracic oncology: Ask questions and chat to consultants from different specialties, all experienced in mentoring and career advice.
Sanjay Popat
On World Cancer Day, we honor everyone who’s been touched by cancer.
We’re announcing a new traveling museum exhibition, The Journey to End Cancer: From Cause to Cure, presented by MD Anderson.
Join us on the journey to end cancer. spr.ly/63327hynKT #OncSky #EndCancer
Why does funding for clinical research matter?
Because #ClinicalTrials depend on sustained investment to advance cancer treatment and provide better outcomes for patients.
👉 Like and reshare this message to highlight why cancer research matters.
#WorldCancerDay #EORTCimpact #CancerResearch
Blue text graphic with black and white text which reads: 'Thousands more men in England offered abiraterone, one of our prostate cancer breakthroughs'
We’re pleased that abiraterone can now be offered to thousands more men affected by prostate cancer. Read more about this decision and what it means: cruk.ink/3LzxTbS
An ESTRO-EPTN Delphi consensus on robustness evaluation in proton therapy, just published in PhiRO - Physics and Imaging in Radiation Oncology.
👉 bit.ly/3Ydzyql
📣 ESTRO 2026 Pre-Meeting Webinars
Get ready for #ESTRO26 with two online pre-meeting webinars ahead of the congress in Stockholm (15–19 May 2026).
Cases will be discussed — we can’t wait to engage with you!
🔗 Info & registration: bit.ly/4pAM9PH
#PMCwebinars #ESTRO26
As part of the World Cancer Day 2026 campaign, IPOS is hosting an insightful webinar to spotlight the key findings from the recently published Lancet Oncology Commission report, “The Human Crisis in Cancer.”
Free for everyone ipos-society.org/event-6480465
📢 Join the ESTRO course in Rome to boost your skills in SRS/SRT for brain metastases & skull base lesions!
📅 26–28 March 2026
⏰ Early deadline: 7 Jan 2026
👨🏫 Course Director: Maximilian Niyazi
🔗 Register: bit.ly/44BetJJ
#ESTROSchool26 #SRS #SRT #Radiotherapy
Effectiveness of Chemotherapy Plus Immunotherapy and Molecular Alterations in Advanced Biliary Tract Cancer: Real-World Evidence From a Single-Center Australian Cohort
@cancer-control.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#carcinoma #biomarkers #oncology #prognosis
📢 The NPCA State of the Nation Report 2025 is OUT!
Find the report, supplementary documents & provider results here www.natcan.org.uk/reports/npca...
@natcan-news.bsky.social @hqip.bsky.social @prostatecanceruk.bsky.social @alison-tree.bsky.social @nhsengland.bsky.social
Please share!
🗣️ New #ESTROWebinar! Management of SCLC in the Immunotherapy Era
🗓 5 Nov | 17:00–18:00 CET
Chaired by Prof Corinne Faivre-Finn & Dr Suraiya Dubash (UK)
💻 Live Q&A with experts!
More info & Registration here: 👉 bit.ly/3KAbjPB
#RadiationOncology #LungCancer #SCLC #Immunotherapy #Webinar
📢 The first-ever ESTRO Clinical Workshop is coming to Vienna | 12–13 Mar 2026! Spots are limited—don’t miss out.
📌 Submit your motivational statement by 22 Oct to secure your place.
💻 Apply now 👉 bit.ly/47wlj5G
#ESTROCLIN26 #ClinicalWorkshop #RadiationOncology
💡 Discover the latest in mutation-driven lung cancer research.
Session 4 with @ruthstraussfdn.bsky.social rings science, debate, and progress together.
📅 13 Nov | 📍 The View, London
🔗 www.btog.org/non-smo...
#LungCancer #LCSM #NonSmokingLungCancer
Calling all Young and Early Career Cancer Nurses (YECCN)
The YECCN MIG is currently looking for 1x MIG Chair, 1x secretary and 8x committee members.
If interested & under 35/working for <5yrs, please email by 5th October, a 300 word expression of interest to:
ukons@media1productions.co.uk
#YECCN
Exciting news! We’ve launched ASCO Edge, an online oncology practice management educational series exclusively available to ASCO members.
Get started today: brnw.ch/21wVVu3
Please check out this from We Own It.
weownit.org.uk/act-now/new-...
Drew Moghanaki and Gerry Hanna Discuss Survival and Toxicity of New Phase 3 Trial in LS-SCLC
@drewmoghanaki.bsky.social @gerryhanna.bsky.social
oncodaily.com/voices/drew-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SCLC #LungCancer
Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the #radiotherapy delineation benchmark case procedure, published in the Green Journal.
👉 Read it before your patients: bit.ly/4fLoatJ
New #radiotherapy innovations are being stifled by the tortuous commissioning process. Patients deserve better! #radonc #oncology #medtwitter
Postcode lottery for new cancer treatments, doctors warn - BBC News www.bbc.co.uk/news/article...
📢 Attending #EAPM2025 this week?
Today, our @eortc.org #QualityofLife Group member Ines Rathgeber will report on the development of an e-learning course focusing on the use of EORTC PRO measures for quality of life assessment in clinical practice 👇
eapm.eu.com/2025-eapm-co...
#CancerResearch
✅ Finished treatment or on maintenance for #PancreaticCancer? We’ve got resources to help.
Find tips on managing side effects, eating well, coping with scanxiety, and staying up to date on the latest research. https://bit.ly/4lX0owd #GuideToAction #LetsWinPC
One Voice for Radiotherapy: Creating World Radiotherapy Awareness Day
oncodaily.com/insight/one-...
#Cancer #Oncology #OncoDaily #Health #Medicine
Putting Patients First: Transforming Cancer Diagnosis, Treatment and Care Through Patient-Centred Approaches.
In this guest editorial, we reflect on why meaningful progress & the delivery of high quality cancer care requires more than technical innovation
www.radiographyonline.com/article/S107...
Today on #WorldLungCancerDay, we reaffirm our mission to support thoracic oncology professionals and advocate for equitable, world-class care for all patients.
Together, we strive to match the best survival rates globally. 💙
#WLCD2025 #LungCancerAwareness #LCSM #lungcancer
Background: Despite extensive research efforts, glioblastoma (GBM) remains a deadly disease with poor prognosis. Although previous studies have identified various cell states within GBM tumors, the molecular mechanism underlying adaptive GBM cell plasticity induced by conventional therapy remains unclear. Methods: We used fluorescent reporters for proneural (PN) and mesenchymal (MES) subtypes to monitor GBM cell plasticity in real-time across multiple patient-derived cell lines. This approach revealed cells that concurrently expressed both proneural and mesenchymal markers. To investigate this unique hybrid population, we implemented a comprehensive methodological approach encompassing bulk and single-cell RNA sequencing, single-cell ChIP sequencing, nuclear proteomics, high-resolution imaging, orthotopic mouse models, clinical dataset analysis, and pharmacological and genetic techniques. This multifaceted strategy allowed us to gain functional and molecular insights into this distinct cellular population. Results: We showed that these hybrid cells are increased by conventional therapies, and are resistant to these therapies. At the molecular level, hybrid cells display significant alterations in chromatin structure and nuclear protein composition, elevated transcriptional activity, Myc activation, and improved transport between the nucleus and cytoplasm. Genetic and pharmaceutical inhibition of the nuclear import/export shuttling machinery, increased in hybrid cells, effectively suppressed adaptive GBM cell plasticity and hybrid identity, thereby enhancing the sensitivity of GBM cells to therapies. Conclusion: Our results indicate that GBM hybrid cells play a crucial role in chemoradiation resistance. The nuclear transport machinery presents a potential therapeutic target for hybrid cells, offering a way to counteract the typical resistance to treatment observed in GBM.
🧠 Why does glioblastoma always outsmart treatment? In our #Neuro-Oncology paper, we identified proneural-mesenchymal hybrid glioblastoma cells that are resistant to therapy and dependent on nuclear import. doi.org/10.1093/neuo...
Short walkthrough below. Let’s dive in! 🧵 (1/9)
#GBM, #BrainTumor
BREAKING NEWS
Scientists at the @icr-ctsu.bsky.social have discovered how to predict which ER+ HER2+ cancers have a higher risk of recurrence in just 2 weeks!
Breaking news - Breast Cancer Breakthrough! #breastcancer
youtube.com/shorts/3rYUU...
